India is at the center of a global effort to develop the vaccine

As the world’s largest supplier of drugs and the world’s manufacturer of 60 ines vaccines, India has long been known as the “pharmacy of the world”.

Now, as the search for the Covid 19 vaccine continues to grow, the country is increasingly playing a strategic and central role in the development, manufacture – and, potentially, future distribution of several possible shots of Covid shots.

With more than 7.5 million cases and 115,000 deaths, India is also one of the countries infected with the virus, second only to the United States.

For the Serum Institute of India in Pune, an agreement has already been reached to develop a 1bn dose of the Oxford / AstraZeneca vaccine, a precursor to the vaccine race. In anticipation of its success, it has already started manufacturing approximately 2 million samples of the vaccine and is conducting Phase 3 human clinical trials on thousands of patients spread across 15 coveted 19 hotspots in India.

This week, the Serum Institute of India said it was confident that the Asterisk vaccine would be ready by December and licensed for distribution in India by March.

Adar Poonawala, CEO of the Serum Institute of India, said he was “very optimistic” that more than one successful vaccine was approaching.

“The record-breaking record of many of these vaccines is very promising, and more than three to four vaccines will be successful next year,” said Pinawala.

The Serum Institute, which also launched human trials this week with an international covalent vaccine, is just one of dozens of Indian companies fleeing to develop many deviant vaccines, producing nearly 200 different varieties worldwide. Being done. .

India’s affairs

Johnson & Johnson, whose code 19 vaccine is also in Phase 3 clinical trials, has successfully contracted with Indian pharmaceutical company Biological E to produce up to 500 million doses.

Bharat Biotech, a Hyderabad-based pharmaceutical company, has a contract with the University of Washington to develop 1bn doses of the intranasal vaccine, which is now in clinical trials, and Indian pharmaceutical company Dev Reddy’s 2/2 in Russia’s India Contract the controversial Sputnik vaccine in 3 stages of human testing and then prepare 100m doses. At least a dozen indigenous vaccines are being developed in India.

All of this is in an important strategic and powerful position in the distribution of vaccines in India and therefore in the global south, especially in local and non-Western countries. “50% of whatever we produce will be set aside for India and the rest will go to low- and middle-income countries,” said Poonawala of the Serum Institute.

To accommodate the millions of promised vaccine vaccines, Poonawala said the company would stop developing other vaccines for the United States and Europe, such as measles, mumps, rubella and hepatitis B, although they are still in development. Provide portable countries.

Expert Datla, CEO of Biological EK, which will develop the Johnson and Johnson vaccines, took a different approach, saying the company is committed to the CoVac vaccine alliance, which 135 countries have agreed to, with equal access. And will push for division. Vaccine

“We have never made decisions on India’s vaccine requirements and trade relations between international organizations like UNICEF.” “So far we have no obligation for India to secure a fixed amount of vaccine,” he said. But in the future, there may be a gap between supply and demand that could put us in that position.

Ironically, while India is the world’s largest producer of vaccines, it faces one of the biggest global challenges in vaccinating its 1.3 billion people.

India has a highly effective immunization program for children and pregnant women, but there is no place for the rest of the population, especially the elderly who are most affected by the corona virus. The already stressful healthcare system has led to epidemics in many areas, and access to healthcare is scarce in many parts of rural India.

India, which suffers from extreme heat, also lacks adequate cold chain facilities, which ensures that the vaccine is kept refrigerated, and therefore will remain effective until it is administered. Go Some vaccines developed may require storage up to 7070C.

There is also the matter of price. The Serum Institute said it expects the vaccine to cost 5. (3.80). The Indian government plans to vaccinate 250 million people by July 2021, meaning that the cost will be met. It will need 1.25 billion.

“Complications in India are about to become extraordinary,” said Gagandeep Shah, an Indian professor of microbiology who is a member of the World Health Organization’s Advisory Committee on Vaccine Safety. “The main concern is scaling and tracing – how do you know who got the vaccine and who didn’t – and the fact that storage regulations are needed.”

Despite this, Kang said there is an even more alarming threat in India, a strong anti-vaccine movement that has already gained momentum in rural areas against measles, mumps and rubella vaccines over the past five years. Kang said he has seen how anti-vaccine plots have spread like wildfire in WhatsApp messages written in the local language, which were very difficult to counter.

“I fear that the longer the Covid 19 vaccination program in India will take, the more ideas and resistance to the vaccine conspiracy will have to be confronted,” Kang said.


Leave a Reply

Your email address will not be published. Required fields are marked *